Myeloma and Related Diseases Registry (MRDR)

The MRDR has reached over 5800 registered patients! A big thank you to all participating sites and patients for your help and support to reach this milestone.

More information

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
5869

Patients accrued

3885

Patients with multiple myeloma

57

Number of approved sites

606

Biobank participants

Latest news

MRDR reaches 5800 patients!
21 Dec 2022

The MRDR has reached 5800 registered patients!

Read more
New MRDR publication
17 Nov 2022

Paper on the second revision of the International Staging System (R2-ISS) accepted for publication!

Read more
MRDR at 4th National Myeloma Workshop
17 Nov 2022

The MRDR was recently represented at the 4th National Myeloma Workshop.

Read more
MRDR Interest Group breakfast at Blood 2022
30 Sep 2022

Thank you to all attendees for contributing to a successful MRDR Interest Group breakfast at Blood 2022!

Read more

Participating organisations